Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00823940 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00823940 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 42 participants.
The verdict
NCT00823940, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The study will investigate whether GSK1362885 is safe and well-tolerated when administered to normal healthy subjects. The study will also measure blood levels of the study drug to determine how the body processes the drug (pharmacokinetics) and what effects the drug has on the body (pharmacodynamics).
Interventions
- DRUG Glucagon
- DRUG GSK1362885
- DRUG Glucagon + GSK1362885
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-01-13 |
| Est. Completion | 2009-04-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00823940
The ClinicalTrials.gov registry entry for NCT00823940 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Glucagon is the first listed.
NCT00823940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00823940 about?
NCT00823940 is a clinical study titled "A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects". The study will investigate whether GSK1362885 is safe and well-tolerated when administered to normal healthy subjects. The study will also measure blood levels of the study drug to determine how the body processes the drug (pharmacokinetics) and what effects the drug has on the body (pharmacodynamic...
What is the current status of trial NCT00823940?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2009-01-13. Estimated completion is 2009-04-27.
What interventions are being tested in trial NCT00823940?
The interventions under investigation include: Glucagon (DRUG), GSK1362885 (DRUG), Glucagon + GSK1362885 (DRUG).
Who is sponsoring clinical trial NCT00823940?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.